This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: When Progress Isn't Good

Cramer said adding up all of Warnaco's assets would take shares dramatically higher than where they trade today. He only hopes company management is listening.

Lightning Round

Here's what Cramer had to say about callers' stocks during the "Lightning Round":

Lululemon Athletica (LULU): "I like Lululemon. They are a well-run company."

Magnum Hunter Resources (MHR): "This is a spec on oil going back to $120. That's where this stock would hit a new all-time high."

Ross Stores (ROST): "This is part of a complex that's being sold. That's a mistake. They should be bought right here."

Hain Celestial Group (HAIN): "Hain did a good job and delivered. I like that story."

Wells Fargo (WFC): "I want you to be big in Wells Fargo. They have 30% of America's mortgage market. Pull the trigger right here."

Pulte Homes (PHM): "It's good, but Toll Brothers (TOL) is the best. I'm going to say don't buy and wait for a pullback."

Cobalt International Energy (CIE): "It's still up for the year but oil has to go up big for it to work. Let's wait for crude to comeback, then this stock will come back."

Realty Income (O): "I like their acquisition. I want to pull the trigger tomorrow."

United Technologies (UTX): "People don't like aerospace, but that's wrong. I think under $80 you have a big opportunity."

Conference Preview

In the middle of this year's conference season, Cramer highlighted what he called his favorite one of the year, the UBS Global Life Sciences Conference, which gets under way Wednesday. He provided viewers with a outline of what to expect during the presentations, which are usually available via webcast.

Cramer said Allergan (AGN) remains a favorite and he's anxious to hear about the company's new indications for Botox and get an update on its pipeline of new products. Gilead (GILD) will also be presenting, and Cramer said that stock is not done going higher despite its recent 10% move up.

Cramer was also bullish on Celgene (CELG), another favorite biotech with a terrific pipeline of new drugs on the way.

Cramer was less enthusiastic about Isis Pharmaceuticals (ISIS) along with Ariad Pharmaceuticals (ARIA) and Affymax (AFFY), three companies that have become too hot to handle.

As a speculative play, Cramer noted NPS Pharmaceuticals (NPSP), a stock that's up 25% for the year. He said the company's two orphan drugs should be receiving news next month, so there's no hurry for investors to buy in on Wednesday's presentation.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs